A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1400 participants.

Also called NCT06993792

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose screening
Phase
Phase 3
Enrolled
  • 1,400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06993792
  • EU CT 2025-521098-14-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, China, Czechia, Germany, Japan, Puerto Rico (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06993792. Randomized; double masking; primary purpose screening. Start 2025-05-15 (actual); primary completion 2027-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Condition
Obesity
Condition
Overweight
Intervention (Drug)
Orforglipron
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06993792
Content hash
d43438f7c11bff939428362526bd3fdd2207a2048aab03c94836e32b579c8f8b